Ovarian Cancer | Specialty

Dr. Markman on Immune Targeting in Ovarian Cancer

November 10th 2016

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the current status of immune targeting as potential treatment for patients with ovarian cancer.

FDA Submission Completed for Niraparib in Ovarian Cancer

November 2nd 2016

A new drug application to the FDA has been completed for niraparib as a maintenance treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

Maintenance Olaparib Improves PFS in Phase III Ovarian Cancer Trial

October 26th 2016

Single-agent olaparib significantly improved progression-free survival compared with placebo in the maintenance setting for patients with advanced BRCA-positive ovarian cancer.

Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian Cancer

October 25th 2016

Results from an expansion cohort of a preliminary clinical trial have shown encouraging activity for a novel antibody-drug conjugate in patients with heavily pretreated advanced ovarian cancer.

Niraparib Expected to Change Practice in Ovarian Cancer

October 19th 2016

The PARP1/2 inhibitor niraparib significantly improved progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.

Streamlined BRCA Testing Program Shows Promise in Ovarian Cancer

October 19th 2016

An interim analysis of an ongoing study showed potential for reducing time and improving acceptance of testing and counseling for patients with ovarian cancer.

Controversy Remains on Addition of VEGF Inhibition Before Interval Debulking in Ovarian Cancer

October 19th 2016

The addition of bevacizumab to neoadjuvant platinum-based chemotherapy led to a significantly increased rate of complete resection at interval debulking in advanced ovarian cancer.

Dr. Jasgit Sachdev on Antibody-Drug Conjugate PF-06647020 in Ovarian Cancer

October 18th 2016

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a phase I study of PF-06647020, an antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in patients with platinum-resistant ovarian cancer.

Low Response Rates Halt First Trial of Abiraterone in Ovarian Cancer

October 17th 2016

The first trial evaluating the efficacy of abiraterone in patients with ovarian cancer has been halted early due to low response, according to results from the CORAL phase II trial, which were presented at the European Society for Medical Oncology Congress.

Counting to 125: The Painstaking Journey to a Landmark Ovarian Cancer Biomarker

October 11th 2016

Robert C. Bast Jr, MD, who led the development of the first clinically relevant blood-based biomarker for ovarian cancer, was honored in the Gynecologic Malignancies category with a 2015 Giants of Cancer Care® award, a program that OncLive launched to recognize leaders in the field.

Dr. Mirza on the Phase III NOVA Trial in Ovarian Cancer

October 9th 2016

Mansoor Raza Mirza, MD, chief oncologist, Rigshospitalet, Copenhagen University Hospital, discusses the results of the phase III NOVA trial during an interview at the 2016 ESMO Congress.

Antibody-Drug Conjugate Active in Pretreated Ovarian Cancer

October 9th 2016

A fourth of patients with heavily pretreated advanced ovarian cancer achieved objective responses with novel antibody-drug conjugate targeting protein tyrosine kinase 7.

Niraparib Highly Effective as Maintenance Therapy for Recurrent Ovarian Cancer

October 8th 2016

Maintenance therapy with niraparib reduced the risk of progression or death by 73% compared with placebo for patients with germline BRCA-positive platinum-sensitive, recurrent ovarian cancer.

High Response Rates With Rucaparib in Heavily Pretreated Ovarian Cancer

October 7th 2016

The majority of heavily pretreated patients with high-grade ovarian cancer and germline or somatic BRCA mutations showed a durable response to rucaparib.

Dr. Bergstrom on XMT-1536 in Ovarian Cancer

October 5th 2016

Donald A. Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses recent data on the new immunoconjugate, XMT-1536.

Dr. Markman on Important Factors of BSO in Ovarian Cancer

October 3rd 2016

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the most important factors of bilateral salpingo-oophorectomy (BSO) to convey to patients with ovarian cancer.

Dr. LoRusso on PARP Inhibitors in Triple-Negative Breast Cancer

September 30th 2016

Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate director, Innovative Medicine, Yale Cancer Center, discusses the role of PARP inhibitors in triple negative breast cancer.

Dr. Charlie Gourley on Olaparib Maintenance in Ovarian Cancer

September 20th 2016

Expert Sheds Light on Important Variables in Preventive Surgery in Ovarian Cancer

September 14th 2016

Several variables are important to consider when undergoing preventive surgery for ovarian cancer, including familial history and age.

Tesaro Initiates Rolling Submission for Niraparib in Ovarian Cancer

September 12th 2016

The FDA has granted a fast track designation to niraparib, allowing the initiation of a rolling submission of data for potential approval for the PARP inhibitor as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.